TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10150847
Drug: Nonsteroidal agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal agents
Study: 1827622
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg orally for 6 days)
Study: 1827622
Drug: Prednisolone (14.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (14.8 mg intravenously)
Study: 7280443
Drug: Octavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octavalent vaccine (serotypes 1, 3, 6A, 7F, 14, 18C, 19F, and 23F)
Study: 7280443
Drug: Heptavalent control
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent control vaccine (serotypes 2, 4, 5, 8, 9N, 12F, and 24F)
Study: 7280443
Drug: Octavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octavalent vaccine
Study: 7280443
Drug: Heptavalent control
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent control vaccine
Study: 30912314
Drug: Lifebox LB-01
Normalized name: spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifebox LB-01 probe with Masimo Rad-87 box (L + M)
Study: 30912314
Drug: Lifebox LB-01
Normalized name: spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifebox LB-01 probe and Lifebox V1.5 box (L + L)
Study: 19117896
Drug: Separate vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate vaccines (DTaP(5), IPV, Hib)
Study: 9618132
Drug: Endoscopic pancreatic
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic pancreatic therapy
Study: 1895044
Drug: Enalapril (E),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (E), 20 mg d‐1
Study: 1895044
Drug: Enalapril (E),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (E), 40 mg d‐1
Study: 1895044
Drug: Slow-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release verapamil (V), 240 mg d‐1
Study: 6200724
Drug: Intravenous isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isosorbide dinitrate infusion (50-200 micrograms/kg/h)
Study: 6193353
Drug: Intravenous hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine (0.15 mg/kg)
Study: 26280945
Drug: Flavonoid-rich orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-rich orange juice (240 ml, 272 mg flavonoids)
Study: 24242903
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 µg bid
Study: 24242903
Drug: Pasireotide 1,950
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 1,950 µg bid
Study: 21060036
Drug: ULABTKA cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: ULABTKA cream applied to hands and feet twice per day for 21 days after the start of capecitabine
Study: 21060036
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied to hands and feet twice per day for 21 days after the start of capecitabine
Study: 21060036
Drug: ULABTKA cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: ULABTKA cream
Study: 9055051
Drug: Pediatric vaccine
Normalized name: hepatitis A pediatric vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric vaccine with lower protein content than adult vaccine; specific dosage not mentioned.
Study: 9055051
Drug: Adult vaccine
Normalized name: hepatitis A adult vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult vaccine (approved); specific dosage not mentioned.
Study: 8419809
Drug: Piracetam (2.4-16.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (2.4-16.8 g daily)
Study: 3532292
Drug: Single nighttime
Normalized name: Flonase Nighttime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single nighttime dose of 800 mg cimetidine
Study: 12205201
Drug: Interventional paired
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventional paired associative stimulation (IPAS) under the influence of dextromethorphan (an NMDA receptor antagonist).
Study: 8916982
Drug: Immediate add-back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate add-back therapy (medrogestone 10 mg/day for 24 weeks)
Study: 8916982
Drug: Deferred add-back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred add-back therapy (placebo for 12 weeks followed by medrogestone 10 mg/day for 12 weeks)
Study: 1607464
Drug: Elastic compression
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastic compression treatment
Study: 6378211
Drug: Long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol (60 mg once a day)
Study: 6378211
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol (20 mg three times a day)
Study: 6378211
Drug: Long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol (60 mg once a day) after 8 days
Study: 6378211
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol (20 mg three times a day) after 8 days
Study: 22389082
Drug: 135 mg
Normalized name: cocaine 135 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg EGCG
Study: 22389082
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (including 135 mg EGCG and placebo)
Study: 22389082
Drug: 270 mg
Normalized name: leucine 270 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mg EGCG
Study: 17297526
Drug: Spirometry (pre-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirometry (pre- and post-bronchodilator)
Study: 16140071
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of gemcitabine 2000 mg in 100 mL of unbuffered saline (n = 11)
Study: 16140071
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly doses of gemcitabine 2000 mg in 100 mL of unbuffered saline for 3 weeks (n = 11)
Study: 16140071
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly doses of gemcitabine 2000 mg in 100 mL of unbuffered saline for 6 weeks (n = 10)
Study: 16140071
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with gemcitabine
Study: 16140071
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects from gemcitabine treatment
Study: 12040677
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg CGS20267 (Letrozole) once daily
Study: 12040677
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg CGS20267 (Letrozole) once daily
Study: 9462768
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine with hyaluronidase (15 U/cc)
Study: 7541854
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor atamestane (400 mg daily for 48 weeks)
Study: 60565
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of tobramycin and lincomycin
Study: 28951372
Drug: Control (gargle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (gargle solution containing chlorhexidine gluconate)
Study: 15958649
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E 1200 mg
Study: 15958649
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E (all doses)
Study: 12653813
Drug: Lofexidine (0.4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine (0.4, 0.8 and 1.6 mg, p.o.)
Study: 12653813
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 and 0.2 mg, p.o.)
Study: 12653813
Drug: Naloxone (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0, 0.1 and 0.3 mg, i.m.)
Study: 7574011
Drug: Milrinone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (all doses combined)
Study: 2038654
Drug: Eutectic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic mixture of local anaesthetics cream (EMLA) applied to the nasal vestibule
Study: 25599968
Drug: Buprenorphine Transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine Transdermal System (BTDS) 10 and 20 mcg/hour
Study: 25599968
Drug: Buprenorphine Transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine Transdermal System (BTDS) 20 mcg/hour
Study: 25599968
Drug: Lower-dose control
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose control (BTDS 5 mcg/hour)
Study: 23742734
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of written advance directive and proxy opinion
Study: 15781537
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg standard morphine
Study: 15781537
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg extended-release morphine (EREM)
Study: 15781537
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg extended-release morphine (EREM)
Study: 14723389
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anabolic-androgenic steroids)
Study: 1914086
Drug: Mitozantrone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitozantrone and prednimustine (12 mg/m2 on day 1 and 130 mg/m2 orally on days 1-5, repeated every 4 weeks)
Study: 6885201
Drug: 250‐mg naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250‐mg naproxen tablet I from AFI
Study: 6885201
Drug: 250‐mg naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250‐mg naproxen tablet II Naprosyn
Study: 31759769
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with relatively high fasting insulin (RHI)
Study: 31759769
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with relatively low fasting insulin (RLI)
Study: 29602570
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) therapy optimization
Study: 29602570
Drug: Nonoptimized Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nonoptimized Adalimumab (ADA) therapy
Study: 22709772
Drug: WEV+ (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEV+ (daily self-monitoring of body weight, step count, F/V intake, and 16 fl oz of water before each main meal)
Study: 22709772
Drug: WEV (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEV (daily self-monitoring of body weight, step count, and F/V intake)
Study: 20626054
Drug: Modulated middle-frequency
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modulated middle-frequency electrical stimulation treatment for 20 min twice a week for 12 consecutive weeks at the Zusanli (ST36) and Sanyinjiao (SP6) acupoints
Study: 10707104
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg miltefosine/day for 28 days
Study: 10707104
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg miltefosine/day for 28 days
Study: 10707104
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg miltefosine/day for 28 days
Study: 10707104
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg miltefosine/day for 7-17 days
Study: 2285202
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 mg/kg)
Study: 2285202
Drug: Prednisolone sodium
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone sodium metasulfobenzoate (Solupred) (1 mg/kg)
Study: 30561087
Drug: Four monthly
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four monthly sessions panretinal photocoagulation (MS-PRP)
Study: 26870678
Drug: Dragons blood
Normalized name: HOMOSALATE 30 mg in 1 mL / OCTINOXATE 60 mg in 1 mL / OXYBENZONE 30 mg in 1 mL TOPICAL CREAM [Dragons Blood SPF15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dragons blood cream
Study: 12421024
Drug: 0.6 g
Normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g omega-3 fatty acids (Maxigard) twice daily
Study: 9467537
Drug: Midodrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (5 mg orally, 30 min before breakfast)
Study: 9467537
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of midodrine and octreotide
Study: 23108628
Drug: Methylprednisolone (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (40-80 mg)
Study: 21646002
Drug: Postoperative infection
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative infection requiring antibiotics
Study: 15173402
Drug: 0.75 g/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g/100 g free phytosterols in gerbil diet
Study: 15173402
Drug: Phytosterol-enriched tortilla
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol-enriched tortilla chips providing 1.5 g/d
Study: 15173402
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with tortilla chips providing 0 g/d phytosterols
Study: 11420737
Drug: Gel padded
Normalized name: Medicated Pad
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel padded glove
Study: 29649054
Drug: Textured insole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Textured insole with physical therapy for 6 weeks
Study: 29649054
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy only for 6 weeks
Study: 27987397
Drug: Prophylactic Amoxicillin‐Clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic Amoxicillin‐Clavulanic acid 1.2g every 8h
Study: 27987397
Drug: Clinically-driven antibiotics
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically-driven antibiotics
Study: 24167479
Drug: Glucose drink
Normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose drink (elevated BGC by approx. 1.5 mmol/l)
Study: 12736280
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy with autologous stem-cell transplant
Study: 12736280
Drug: Standard conventional-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conventional-dose combination chemotherapy
Study: 10695838
Drug: Disulfiram during
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram during the first month of treatment
Study: 10695838
Drug: Matching of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching of patients with the structure of treatment
Study: 10695838
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of the motivation phase and active treatment phase
Study: 1608318
Drug: Metoclopramide 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.15 mg/kg (iv)
Study: 1608318
Drug: Ephedrine 0.5
Normalized name: Ephedrine 0.5% Nasal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.5 mg/kg (im)
Study: 1608318
Drug: Ephedrine 1
Normalized name: ephedrine 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 1 mg/kg (im)
Study: 26920611
Drug: β-blocker therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker therapy (various types including carvedilol, metoprolol succinate, bisoprolol, atenolol, metoprolol tartrate)
Study: 26920611
Drug: Patients discharged
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients discharged on 50% of target dose or greater
Study: 25174952
Drug: Oral nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicorandil 20 mg once daily for 1 week before and 6 months after PCI
Study: 20958143
Drug: Lidocaine solution
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine solution for inhalation (LSI; 40 mg twice daily; eFlow nebulizer)
Study: 17413092
Drug: High physical
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High physical activity (HPA) treatment with a goal of 2500 kcal/wk
Study: 17413092
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral treatment (SBT) with an exercise goal of 1000 kcal/wk
Study: 1538178
Drug: Iontophoresed morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresed morphine HCl
Study: 1538178
Drug: Iontophoresed lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresed lactated ringers solution
Study: 6434024
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral plus nasal beclomethasone diproprionate
Study: 29752853
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 mcg kg‐1
Study: 26350351
Drug: Goserelin 10.8
Normalized name: goserelin 10.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 10.8 mg (3-monthly)
Study: 26350351
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg (monthly)
Study: 24660763
Drug: Carbonyl iron
Normalized name: Carbonyl Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbonyl iron (45 mg daily)
Study: 19884264
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg daily for 12 months
Study: 18020541
Drug: Transdermal drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal drug delivery system (TDDS) of metoprolol tartrate applied for 48 hours
Study: 18020541
Drug: Conventional marketed
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional marketed tablet of metoprolol tartrate (100 mg)
Study: 18020541
Drug: Transdermal drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal drug delivery system (TDDS) of metoprolol tartrate
Study: 12474653
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) used as an adjuvant to anesthetics; shock-dose injection of 30-50 mg/kg and continual infusion at 500 mg/h for 20 hours.
Study: 7722125
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion alone
Study: 28508455
Drug: Alpha-blocker only
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker only (n=111)
Study: 28508455
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (alpha-blocker + anticholinergic, n=110)
Study: 18392221
Drug: Radioimmunoscintigraphy (RIS)
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioimmunoscintigraphy (RIS) using monoclonal antibody against human milk fat globule labeled with technetium-99m (99m)Tc
Study: 14534715
Drug: beta-carotene (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-carotene (75 mg/day for 3-month cycles with one month intercycle intervals for 3 years)
Study: 2059815
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tamoxifen daily and optimal surgery
Study: 6735044
Drug: Gelox (shielding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelox (shielding antacid) after 500 mg of AAS
Study: 30696977
Drug: Cholecalciferol (vitamin
Normalized name: cholecalciferol (vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (vitamin D) 50,000 IU weekly for 3 months
Study: 25205201
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg twice daily plus amoxicillin 1 g thrice daily for 14 days
Study: 25205201
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg twice daily plus amoxicillin 1 g thrice daily for 14 days
Study: 10515673
Drug: HRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT with progestin for 10 days during 12 week cycles of estrogen (17beta‐estradiol 2 mg per day, reduced to 1 mg during last 6 days)
Study: 10515673
Drug: HRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT with progestin for 10 days during monthly cycles of estrogen (17beta‐estradiol 2 mg per day, reduced to 1 mg during last 6 days)
Study: 7640054
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ifosfamide (9 g/m2 over 72 h)